Elizabeth L Tsui

Ms. Elizabeth L Tsui

orcid

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
22 February 2023 in F&S Reports
Verified
Journal Article
Open access
ETElizabeth L Tsui
Elizabeth L Tsui
CHCourtney J. Harris
Courtney J. Harris
ERErin E. Rowell
Erin E. Rowell
Monica M LarondaMonica M Laronda
Monica M Laronda
To study ovarian gross morphologic and subanatomic features across pubertal development. Prospective cohort study. An academic medical center with specimens collected from 2018–2022. Tissue was obtained from prepubertal and postpubertal participants (0.19–22.96 years) undergoing ovarian tissue cryopreservation before treatment that put them at a significantly or high increased risk of developing premature ovarian insufficiency. Most participants (64%) had not received chemotherapy at tissue collection. None. Ovaries procured for fertility preservation were weighed and measured. Ovarian tissue fragments released during processing, biopsies used for pathology, and hormone panels were analyzed for gross morphology, subanatomic features, and reproductive hormones. Graphical analysis of best-fit lines determined age at maximum growth velocity. Prepubertal ovaries were significantly (1.4-fold and 2.4-fold) smaller than postpubertal ovaries by length and width and 5.7-fold lighter on average. Length, width, and weight grew in a sigmoidal pattern with age. Prepubertal ovaries were less likely to display a defined corticomedullary junction (53% vs. 77% in postpubertal specimens), less likely to have a tunica albuginea (22% vs. 93% in postpubertal specimens), contained significantly more (9.8-fold) primordial follicles, and contained primordial follicles at significantly deeper depths (2.9-fold) when compared with postpubertal ovaries. Ovarian tissue cryopreservation is a resource to study human ovarian biology and pubertal development. Maximum growth velocity occurs late within the pubertal transition (Tanner 3+) after changes in subanatomic features. This ovarian morphology model adds to foundational knowledge of human ovarian development and supports ongoing transcriptomics research.

6 April 2024 in Journal of the Endocrine Society
Verified
Journal Article
Open access
PDF file
ETElizabeth L Tsui
Elizabeth L Tsui
HMHannah B McDowell
Hannah B McDowell
Monica M LarondaMonica M Laronda
Monica M Laronda
The last 20 years have seen substantial improvements in fertility and hormone preservation and restoration technologies for a growing number of cancer survivors. However, further advancements are required to fill the gaps for those who cannot use current technologies or to improve the efficacy and longevity of current fertility and hormone restoration technologies. Ovarian tissue cryopreservation (OTC) followed by ovarian tissue transplantation (OTT) offers those unable to undergo ovarian stimulation for egg retrieval and cryopreservation an option that restores both fertility and hormone function. However, those with metastatic disease in their ovaries are unable to transplant this tissue. Therefore, new technologies to produce good-quality eggs and restore long-term cyclic ovarian function are being investigated and developed to expand options for a variety of patients. This mini-review describes current and near future technologies including in vitro maturation, in vitro follicle growth and maturation, bioprosthetic ovaries, and stem cell applications in fertility restoration research by their proximity to clinical application.

25 May 2024 in Bioengineering
Verified
Journal Article
Open access
PDF file
HMHannah McDowell
Hannah McDowell
KMKathryn L McElhinney
Kathryn L McElhinney
ETElizabeth L Tsui
Elizabeth L Tsui
Monica M LarondaMonica M Laronda
Monica M Laronda
While ovarian tissue cryopreservation (OTC) is an important fertility preservation option, it has its limitations. Improving OTC and ovarian tissue transplantation (OTT) must include extending the function of reimplanted tissue by reducing the extensive activation of primordial follicles (PMFs) and eliminating the risk of reimplanting malignant cells. To develop a more effective OTT, we must understand the effects of the ovarian microenvironment on folliculogenesis. Here, we describe a method for producing decellularized extracellular matrix (dECM) hydrogels that reflect the protein composition of the ovary. These ovarian dECM hydrogels were engineered to assess the effects of ECM on in vitro follicle growth, and we developed a novel method for selectively removing proteins of interest from dECM hydrogels. Finally, we validated the depletion of these proteins and successfully cultured murine follicles encapsulated in the compartment-specific ovarian dECM hydrogels and these same hydrogels depleted of EMILIN1. These are the first, optically clear, tailored tissue-specific hydrogels that support follicle survival and growth comparable to the “gold standard” alginate hydrogels. Furthermore, depleted hydrogels can serve as a novel tool for many tissue types to evaluate the impact of specific ECM proteins on cellular and molecular behavior.

3 June 2024 in Fertility and Sterility
Verified
Journal Article
Closed access
MBMelissa J. Bak
Melissa J. Bak
DFDoris Farje
Doris Farje
ETElizabeth L Tsui
Elizabeth L Tsui
TLTimothy B. Lautz
Timothy B. Lautz
Monica M LarondaMonica M Laronda
Monica M Laronda
ERErin E Rowell
Erin E Rowell

10 April 2026 in Molecular & Cellular Proteomics
Verified
Journal Article
Open access
NFNickolas P. Fisher
Nickolas P. Fisher
VKVijaya Lakshmi Kanchustambham
Vijaya Lakshmi Kanchustambham
ETElizabeth L Tsui
Elizabeth L Tsui
CLChelsea Lock
Chelsea Lock
TXTian Xu
Tian Xu
NKNeil Kelleher
Neil Kelleher
Ovarian tissue cryopreservation (OTC) is a fertility preservation strategy available to prepubertal patients undergoing gonadotoxic treatment who are at risk of developing premature ovarian insufficiency or for those whose treatment cannot be delayed. While cryopreserved tissue can be utilized for ovarian tissue transplantation (OTT) to restore hormone function and fertility in some of these individuals, those with a high risk of malignant cell reintroduction currently have no options. In vitro Maturation (IVM) of isolated immature oocytes from prepubertal patients is not yet successful enough for the clinic, necessitating study of the molecular factors influencing oocyte quality for IVM success. In this study, we characterized intact proteoforms from single human oocytes obtained from OTC and tissue donation in a donor cohort aged 2-33 years old to identify changes in the oocyte proteome across the pubertal transition. Utilizing single cell proteoform imaging mass spectrometry (scPiMS), which employs a sampling probe to raster over single cells coupled to individual ion mass spectrometry (I2MS) detection, we identified 559 proteins and 769 unique proteoforms across 28 oocytes from 8 donors, with an average of 78 unique proteoforms per oocyte. We used scPiMS to selectively sample oocytes and cumulus granulosa cells from single cumulus oocyte complexes (COCs) to identify proteoforms specific to these cell types. Finally, we determined proteoform landscapes for members of the oocyte-specific subcortical maternal complex (SCMC), KHDC3 and OOEP, and found new proteoforms that differ with donor age. Together, these first-in-class observations provide a foundation for understanding protein-level changes in oocyte biology across puberty to ultimately improve the efficiency of IVM and make fertility restoration options accessible for more patients.

11 October 2025 in Biology of Reproduction
Verified
Journal Article
Closed access
MMMarie-Charlotte Meinsohn
Marie-Charlotte Meinsohn
JCJosephine Cleverdon
Josephine Cleverdon
AMAlana M Mermin-Bunnell
Alana M Mermin-Bunnell
KMKarine de Mattos
Karine de Mattos
PMPhoebe May
Phoebe May
DPDavid Pépin
David Pépin
Anti-Müllerian hormone is a factor secreted by granulosa cells of growing follicles that regulates many aspects of ovarian function, including primordial follicle activation and early follicle development through inhibitory feedback. Treatment with exogenous anti-Müllerian hormone at supraphysiological levels can inhibit follicular development and prevent ovulation in mice, rats, and cats. Single-cell transcriptomic analysis of ovaries from mice treated postnatally with anti-Müllerian hormone identified a distinct quiescence signature in granulosa cells. Herein, we further characterized the anti-Müllerian hormone -induced quiescent cell state and drew parallels to developmental senescence by describing a reversible “quiescence-associated secretory phenotype.” This state was characterized by the induction of several hallmarks of senescence, including inhibition of proliferation (reduced KI67), upregulation of markers of senescence (Cdkn1a, Fn1, Cebpb, Timp3), and chemokines and their receptors (Cxcl14, Cxcl12, Ccl12, Ccl21, Cxcr2). However, quiescence-associated secretory phenotype did not recapitulate other senescence hallmarks, such as activation of beta-galactosidase activity or permanent exit from the cell cycle. Similar to classical senescence, we found that anti-Müllerian hormone induced quiescence-associated secretory phenotype, in part, through the upregulation of cyclin-dependent kinase inhibitors (Cdkn1a, Cdkn1b, and Cdkn1c) in granulosa cells and oocytes of mouse and human ovaries. Finally, we showed that the quiescence-associated secretory phenotype state could be reversed within a month of discontinuing anti-Müllerian hormone treatment. This recovery was marked by the return of growing primary, secondary, and antral follicles. In conclusion, these data suggest that anti-Müllerian hormone can pause follicle development by inducing quiescence-associated secretory phenotype, a reversible senescent-like state, which may benefit fertility preservation.